RecruitingPhase 3NCT05477576

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Studying Neuroendocrine tumor of pancreas

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: RayzeBio, Inc.
Principal Investigator: Ye Yuan, MD
RayzeBio Sr. Medical Director
Intervention: RYZ101(drug)
Enrollment: 338 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2030

Study locations (30)

Research Facility, Phoenix, Arizona, United States
Research Facility, Duarte, California, United States
Research Facility, Irvine, California, United States
Research Facility, Los Angeles, California, United States
Research Facility, Palo Alto, California, United States
Research Facility, San Francisco, California, United States
Research Facility, New Haven, Connecticut, United States
Research Facility, Washington D.C., District of Columbia, United States
Research Facility, Jacksonville, Florida, United States
Research Facility, Miami, Florida, United States
Research Facility, Tampa, Florida, United States
Research Facility, Atlanta, Georgia, United States
Research Facility, Iowa City, Iowa, United States
Research Facility, Lexington, Kentucky, United States
Research Facility, Glen Burnie, Maryland, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05477576 on ClinicalTrials.gov

Other trials for Neuroendocrine tumor of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine tumor of pancreas →

← Back to all trials